New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 12, 2014
15:41 EDTSQNMSequenom reports preliminary FY13 total revenue around $162M, consensus $165.45M
The company announced preliminary 2013 performance results. The company sees total revenue of approximately $162M, showing growth of approximately 81% year-over-year for 2013. Diagnostic services revenues of approximately $120M, as compared to $46.5M in 2012. Diagnostic services revenues continue to be recorded primarily as cash is received. The company added that it sees high margin stable revenue in the Sequenom Bioscience business of over $42M. Total cash, cash equivalents and marketable securities as of December 31 were approximately $71M and cash burn was reduced to approximately $14M for Q413. Unrecorded diagnostic accounts receivable are estimated to be $46M to $51M as of December 31.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2014
21:54 EDTSQNMPiper Jaffray to hold a bus tour
Subscribe for More Information
August 19, 2014
11:32 EDTSQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use